Cargando…

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcomes for advanced melanoma in US community oncology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowey, C. Lance, Liu, Frank Xiaoqing, Black-Shinn, Jenny, Stevinson, Kendall, Boyd, Marley, Frytak, Jennifer R., Ebbinghaus, Scot W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811239/ https://www.ncbi.nlm.nih.gov/pubmed/29252916 http://dx.doi.org/10.1097/CJI.0000000000000204

Ejemplares similares

Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021)

Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article)
por: Cowey, C. Lance, et al.
Publicado: (2019)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment
por: Liu, Frank Xiaoqing, et al.
Publicado: (2019)

Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
por: Reynolds, Craig, et al.
Publicado: (2018)

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting
por: Cowey, Charles L., et al.
Publicado: (2020)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
por: Hamid, Omid, et al.
Publicado: (2018)

Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review
por: Copley-Merriman, Catherine, et al.
Publicado: (2018)

The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma
por: John, Lijo, et al.
Publicado: (2015)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
por: Cowey, C. Lance, et al.
Publicado: (2020)

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
por: Liu, Frank Xiaoqing, et al.
Publicado: (2017)

Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study
por: Liu, Frank Xiaoqing, et al.
Publicado: (2019)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma
por: Lorenzi, Maria, et al.
Publicado: (2019)

Evaluation of dosing strategy for pembrolizumab for oncology indications
por: Freshwater, Tomoko, et al.
Publicado: (2017)

Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model
por: Walker, Brigham, et al.
Publicado: (2020)

Identification of Research Priorities in Exercise Oncology: A Consensus Study
por: Morris, Mhairi, et al.
Publicado: (2020)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

Institution-Specific Strategies for Head and Neck Oncology Triage During the COVID-19 Pandemic
por: Freeman, Michael H., et al.
Publicado: (2022)

New developments in the management of advanced melanoma – role of pembrolizumab
por: Improta, Giuseppina, et al.
Publicado: (2015)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
por: Rizzetto, Giulio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8obg3krnfk3vb0vl6ktjbs3i6u